The Burden of Residual SymptOms That Complicate the Life of Patients Who Have Suffered a new Coronavirus Infection (THROW study).


Journal

Kardiologiia
ISSN: 0022-9040
Titre abrégé: Kardiologiia
Pays: Russia (Federation)
ID NLM: 0376351

Informations de publication

Date de publication:
30 Oct 2022
Historique:
received: 08 06 2022
accepted: 01 07 2022
entrez: 17 11 2022
pubmed: 18 11 2022
medline: 22 11 2022
Statut: epublish

Résumé

Aim      To evaluate the prevalence of residual symptoms in patients hospitalized for novel coronavirus infection at 8 months after discharge and the severity of such symptoms depending on demographic characteristics, concurrent diseases, and specific features of the acute period of COVID-19.Material and methods  This study included the patients who were managed for novel coronavirus infection in a COVID-19 hospital and provided their consent to participate in the study (98 patients). At 8 months after discharge from the hospital, a structured telephone interview was performed.Results Only 40 % of patients treated for COVID-19 did not have any complaints at 8 months after discharge from the hospital. The most frequent complaints in the long term were fatigue (30.5 %), weakness (28.4 %), shortness of breath (23.2 %), arthralgia (22.1 %), myalgia (17.9 %), and anosmia (15.8 %). The background of chronic diseases and obesity, percentage of lung damage according to CT data, and the requirement for oxygen support during the acute period in our sample were not related with the presence of symptoms in the long term. The presence and severity of symptoms during the long term were not determined by the clinical condition, volume of lung damage, or requirement for oxygen support but were related with the gender and severity of inflammation upon admission.Conclusion      Independent predictors for persistence of symptoms in the patient sample with severe novel coronavirus infection during the long term included chest and joint pain during the stay in the hospital, female gender, and increased levels of C-reactive protein upon admission.

Identifiants

pubmed: 36384406
doi: 10.18087/cardio.2022.10.n2198
doi:

Substances chimiques

Oxygen S88TT14065

Types de publication

Journal Article

Langues

rus eng

Sous-ensembles de citation

IM

Pagination

26-34

Auteurs

Ya A Orlova (YA)

Lomonosov Moscow State University, Moscow.

Yu V Mareev (YV)

Lomonosov Moscow State University, Moscow; National Medical Research Center of Therapy and Preventive Medicine, Moscow.

V Yu Mareev (VY)

Lomonosov Moscow State University, Moscow.

A G Plisyk (AG)

Lomonosov Moscow State University, Moscow.

Yu L Begrambekova (YL)

Lomonosov Moscow State University, Moscow.

Z A Akopyan (ZA)

Lomonosov Moscow State University, Moscow.

D M Sakaeva (DM)

Lomonosov Moscow State University, Moscow.

D D Loginova (DD)

Lomonosov Moscow State University, Moscow.

A S Shurygina (AS)

Lomonosov Moscow State University, Moscow.

A A Kamalov (AA)

Lomonosov Moscow State University, Moscow.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH